Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0051—Estrane derivatives
  • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers

Definitions

• This invention relates to ⁇ 9(l l)-dehydro-8-isoestrone (VI), which can also be named 8 ⁇ -3-hydroxyestra-l,3,5(10),9(l l)tetraen-17-one, to the process for its preparation, to pharmaceutical compositions containing said ⁇ 9(l l)-dehydro-8- isoestrone (VI) and to the use of said ⁇ 9(l l)-dehydro-8-isoestrone (VI) for modifying the balance between bone production and bone resorption and as an antioxidant in a host animal, including man.
• VI ⁇ 9(l l)-dehydro-8-isoestrone
• Osteoporosis is a skeletal disorder which is evidenced by a decrease in bone density throughout the body.
• both the bone mineral calcium phosphate called
• hydroxyapatite and the bone matrix (major protein called “collagen”) are slowly lost. This condition may begin to occur in humans as early as age 30. In general, the process is more rapid in postmenopausal women than in men. However, after age 80 there is no sex difference in the incidence of osteoporosis. In the course of 10 to 20 years of bone loss there may be symptoms of back pain and X-ray evidence of deformation of the spine. At older ages, the brittleness of the bones becomes evident by the ease with which the proximal femur ("hip”) fractures. Osteoporosis is the most common cause of fractures in people over age 45.
• Bone break ⁇ down bone resorption
• osteoporosis A survey indicates that in the United States there may be fifteen to twenty mil ⁇ lion people afflicted with osteoporosis [W.A. Peck (Chairman), NIH Osteoporosis Consensus Conference, J. Am. Med. Assoc, 10, 252:799-802 (1984)].
• Various types of osteoporosis are designated according to special conditions believed to be causative: senile (aging); post-menopausal (female loss of estrogenesis); disuse (chronic immobi ⁇ lization); steroid (long term steroid treatment as in arthritis). Osteoporosis may also be manifested in dental problems since the mandible appears to lose mass more rapidly than any other bone. Thus, periodontal disease involving a loosening of the adult teeth may be an early sign of osteoporosis.
• the mechanism of bone loss is at present poorly understood. Moreover, the present methods of treatment are generally unsatisfactory. These include anabolic agents, various drugs containing phosphorous, Vitamin D, calcium salts, fluorides and calcitonin.
• Estrogen replacement therapy has been the therapy of choice for osteoporosis in post-menopausal women.
• Physical therapy is another method currently used to treat osteoporosis since immobilization can cause osteoporosis at any age. Thus, many physicians believe that exercise and physical therapy can prevent the progression of the disease in elderly patients. However, physical therapy can be harmful for patients with fractures and, moreover, overstrenuous exercise can cause fractures in patients with severe osteoporosis.
• the most promising therapeutic approach to the treatment of osteoporosis is the administration of agents which have been designed to modify the balance between the rate of bone production and the rate of bone resorption in such a manner that the ratio of the former to the latter is increased, resulting in no net bone loss. After the previously occurred bone losses have been restored, a steady state is reached where the rate of bone production and rate of bone resorption are equal.
• Such a modification may be effected by stimulating the physiological mechanism of bone deposition, i.e., bone formation, or by retarding the mechanism of bone resorption, or both.
• Drugs presently in use or in the experimental stages for accomplishing these purposes include phospho- nates, calcitonin and mithramycin. However, all of these drugs suffer serious drawbacks.
• Mithramycin an antibiotic, has anti-tumor activity together with hypocalcemic activity, causing a reduction of serum calcium which in turn is believed to be indicative of a decrease in the relative rate of bone resorption ⁇ i.e., bone resorption relative to bone production.
• Side effects include renal and hepatic toxicity as well as nausea.
• the organic phosphonates have side effects which include extra- skeletal calcification, hypotension and renal failure.
• Calcitonin presents an immunolog- ical problem because it is commonly derived from a non-human source.
• This invention relates to the compound of formula (VI)
• the compound of the present invention (NI) is a double bond isomer of equilin represented by the formula (Tfl)
• the compound of the present invention (VI) is useful for 1) the treatment or prevention of estrogen deficiency induced bone loss 2) reducing cardiovascular plaque formation leading to decreased mortality
• Still another object of this invention is to provide a process for the treatment of a host animal in order to prevent the deterioration of existing healthy bone tissues in said host animal. It is possible that these agents could also be of utility in the treatment of hypercalcemia of malignancy, Paget's disease, and the arthritides.
• the compound of formula (VI) of this invention is used alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard medical practice. For example, they are administered orally in the form of capsules, tablets, suspensions or solutions or they may be injected parenterally.
• Capsules and tablets are the preferred mode of administration.
• parenteral adminis ⁇ tration they can be used in the form of a sterile solution containing other solutes, for example enough saline or glucose to make the solution isotonic.
• the capsule and tablet compositions contain the active ingredient in admixture with non-toxic pharmaceutical excipients known to be suitable in the manufacture of capsules and tablets.
• Suitable pharmaceutical excipients are, for example, starch, milk sugar, certain types of clay and so forth.
• the tablets can be uncoated or they can be coated by known techniques so as to delay disintegration and absorption in the gastro- intestinal tract and thereby provide a sustained action over a longer period.
• the aqueous suspensions of the compounds of formula (VI) contain the active ingredient in admixture with one or more non-toxic pharmaceutical excipients known to be suitable in the manufacture of aqueous suspensions.
• Suitable excipients are, for example, methylcellulose, sodium alginate, gum acacia, lecithin and so forth.
• the aqueous suspensions can also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
• Non-aqueous suspensions can be formulated by suspending the active ingredi ⁇ ent in a vegetable oil for example, arachis oil, olive oil, sesame oil, or coconut oil, or in mineral oil, for example liquid paraffin, and the suspension may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. These compositions can also contain a sweetening agent, flavoring agent and antioxidant.
• the dosage of the compound of formula (VI) will vary with the form of admin- istration, and the particular compound chosen. Furthermore, it will vary with the par ⁇ ticular host as well as the age, weight and condition of the host under treatment, as well as with the nature and extent of the symptoms. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circum- stances is reached.
• the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects.
• the effective amount of the compounds for oral administration can usually range from about 200 mg to 1200 mg/day in single or divided doses although, as aforementioned, variations will occur. However, a dosage level that is in the range of from about 500 mg to
• 900 mg/day in single or divided doses is employed most desirably for oral administra ⁇ tion in order to achieve effective results.
• ⁇ 9(l l)-dehydro-8-isoestrone (VI) would be administered to humans at a daily dose of 200 mg to 1200 mg.
• the useful osteoporotic activity of the compound of formula (VI) are demon ⁇ strated by standard pharmacological tests, for example, the test designated: Bone Resorption Assay: ⁇ Ca Release from Rat Limb Bones.
• This assay is to identify compounds that inhibit basal or stimu ⁇ lated bone resorption in culture.
• Timed pregnant Sprague-Dawley CD ® rats (Charles River) are administered 100 ⁇ Ci 45 CaCl2 (NEN calcium -45 NEZ-013) in 100 ⁇ l of 0.9% saline, subcuta- neously, on day 18 of gestation.
• the rats are sacrificed the following day by CO 2 asphyxiation.
• the fetuses are removed and the right forelimbs excised and placed in a Petri dish containing ice cold explant medium consisting of modified BGJ b -Fitton Jackson media (custom formulation, Gibco No. 78-0088) adjusted to pH 7.3 to which 10 mM TES is added.
• the modified BGJ b media is obtained without salts, glucose or bicarbonate and is supplemented before use with 0.1 mM MgCt ⁇ , 1.25 mM CaC- 2 , 5.3 mM KCl, 0.7 mM MgSO , 130 mM NaCl, 1.0 mM N-1H 2 PO 4 , 1 g L glucose, 50 mg L Na acetate and 100 U/mL penicillin G.
• the medium is sterilized by passage through a 0.2 ⁇ M filter (Nalge). Under a dissecting microscope, the bones are gently cleaned of adherent tissue and the cartilaginous ends removed.
• the midshafts are placed, individually, on 3x3 mm squares of filter paper (Gelman GN-6 metricel filters; 0.45 ⁇ M pore size) which rest on stainless steel screens in wells of 24-well culture plates containing 0.5 mL of preincubation medium.
• the preincubation medium is brought to 37 ⁇ C prior to transfer of bones.
• the preincubation medium consists of the modified BGJ b medium (with salts and glucose as above), pH
• the bones are transferred on their screen/filter paper supports to new plates containing, in a total volume of 0.5 mL/well at 37°C, the test compound diluted in preincubation medium supplemented with 15% heat inactivated horse serum (Gibco No. 230-6050), pH 7.3, with or without a bone resorption stimulating agent (e.g. parathyroid hormone [PTH] or interleukin-1 [JJ -1]).
• a bone resorption stimulating agent e.g. parathyroid hormone [PTH] or interleukin-1 [JJ -1]
• dilutions are made from the appropriate stock solution with medium.
• CALCULA ⁇ ONS The percentage of bone 5 Ca released into the medium is determined as follows:
• Results are normally expressed as the ratio of the percent 5 Ca release of the experimental group versus the appropriate vehicle control.
• the useful osteoporotic activity of the compound of formula (VI) can be further demonstrated by the test designated: Basal Bone Resorption Assay: 42Ca Release from Rat Limb Bones.
• This assay is to test stimulators and inhibitors of bone resorption in vitro.
• the release of 45 Ca from in vitro labeled murine bone explants into the cul ⁇ ture media is taken as an index of bone resorption.
• Rat pups are labelled in vitro by injecting pregnant dams (18 days) with 100 ⁇ Ci of 45 Ca.
• Bones are separated into 3 categories: calvaria halves, tibiae and ulnae/radii. Groups of eight (per bone group) are randomly placed in 24-well culture plates containing 0.5 mL of control media. Cultures are maintained at 37°C in a humidified incubator of 95% air: 5%CO2- These bones are incubated for 24 hours, media is aspirated from the bones and replaced with fresh media containing test substances. Each bone group has a control group of 8 and a dead bone group of 8. The devitalized cultures are obtained by heat ⁇ ing the bones in medium at 55°C for 60 minutes. The bones are incubated at 37°C for an additional 72 hours.
• a 100 microliter aliquot of media is removed and placed in a scintillation vial.
• Ten mL of Aquasol is added, the ⁇ Ca is quantified in a scintillation spectrometer. Bones are rinsed in saline, placed in a scintillation vial, hydrolyzed overnight in 0.75 mL 6N HC1 at room temperature. The hydrolyzed bone solution is neutralized by the addition of 2.25 mL of 2N NaOH, followed by 10 mL of Aquasol, the ⁇ Ca content is determined by scintillation spectrometry.
• ⁇ Ca release into culture medium from the 24-96 hour period is individually compared to ⁇ Ca release in control cultures and to devitalized bone via Dunnett's test.
• the useful osteoporotic activity of the compound of formula (NI) can be further demonstrated by the test designated: Denervation Induced Osteopenia in Rats.
• This assay is to evaluate the effect, in rats, of agents on the re ⁇ duction in bone mass (osteopenia) induced by immobilization resulting from surgical severance (denervation) of the sciatic nerve.
• mice Female, Sprague Dawley CD® rats, ovariectomized or intact, weighing 225 to 250 g, obtained from Charles River are used. The animals are housed in plastic cages
• the animals are randomly divided into groups of 6 to 10 rats/group. Each rat is weighed, anesthetized with an intraperitoneal administration of 100 mg/kg ketamine (Bristol Laboratories, Syracuse, ⁇ Y) and 0.75 mg/kg Acepromazine (Aveco, Ft. Dodge IA).
• the left hind limb is shaved and denervated by making a lateral incision parallel to the femur and by surgically removing half of a centimeter of the sciatic nerve adjacent to caudofemoralis and adductor brevis muscles. The incision is closed with wound clips.
• the rats are housed in cages with absorbent bedding to minimize additional trauma to the immobilized limb. A 24 hour post-surgery recovery period is allowed before the initiation of the drug treatment.
• the concentration of the drug stock is calculated to be delivered in a volume of 0.1 mL/100 gram body weight.
• the drug solution or a uniform suspension is prepared in 1% Tween 80 in normal saline.
• the drugs are administered via oral or parenteral routes daily (five times a week) for four weeks.
• a sequential triple labeling of mineralized tissue is employed to determine the osseous changes (especially the bone formation) and the mineralization rates.
• Each animal is administered 90 mg/kg Xylenol orange (Fisher Scientific Company), S.C., 15 mg/kg Calcein (Sigma Chemical Company), S.C. and 15 mg/kg Demeclocycline (Sigma Chemical Company), i.p., approximately 21 days, 10 days and 2 days prior to the termination of the study, respectively.
• each rat is weighed, anesthetized with an intraperitoneal administration of 100 mg/kg ketamine with 0.75 mg/kg Acepromazine and approximately 4 mL of blood collected via cardiac puncture.
• the anesthetized rats are euthanized by exposure to carbon dioxide.
• the femora and tibiae from both limbs are dissected free of soft tissue.
• Femora are ashed at ⁇ 1100°C for 16 hours using a muffle furnace.
• Proximal tibia are fixed, dehydrated and embedded undecalcified in a methyl methacrylate-glycol methacrylate mixture.
• Longitudinal tissue sections (10 microns) are prepared on a Polycut S microtome (Reichert). Staining is performed on free- floating sections using a modified Goldner's stain, which are then mounted and coverslipped.
• Cancellous bone content in the proximal tibia is quantified (as two dimensional bone mineral area [B.Ar]) with an image analysis processing device (software developed by Drexel University).
• the areas of the tibia selected for cancellous bone content evaluation are the primary and secondary spongiosa.
• the epiphyseal growth plate-metaphyseal junction is oriented parallel to the abscissa of the digitizing screen. Bone elements 1.7 mm (secondary spongiosa) and 0.2 mm (primary spongiosa) from the growth plate and equidistant from the flanking cortical elements are then quantified as described above.
• the total area evaluated is 2.30 mm wide and 1.45 mm deep, constituting a 3.34 mm 2 area.
• Body weight, femur mass (dried or ashed) and trabecular (cancellous) bone mineral area (B.Ar) are determined.
• the difference (both absolute and percent change) in femur mass and bone mineral area between intact (control) and denervated limbs of a treatment group are compared with that for the vehicle group using a one-way analysis of variance with Dunnett's test, or other multiple comparison methods.
• the present invention provides a method for the treatment of a host animal in order to modify the balance between the rate of bone resorption and the rate of bone deposition in said host animal whereby the ratio of said rate of bone resorption to said rate of bone deposition is reduced, comprising adminis- tering to said host animal an amount, sufficient to modify said balance and reduce said ratio, of ⁇ 9(ll)-dehydro-8-isoestrone (NI).
• NI ⁇ 9(ll)-dehydro-8-isoestrone
• ⁇ 9(l l)-dehydro-8-isoestrone (VI) in accordance with this invention can be supplemental to other regimens for the treatment of osteoporosis or periodontitis.
• the administration of ⁇ 9(ll)-dehydro-8-isoestrone (VI) can be supplemental to the 600 mg to 1200 mg daily intake of calcium as calcium phosphate or calcium carbonate.
• the administration of ⁇ 9(l l)-dehydro-8- isoestrone (VI) can be supplemental to estrogen replacement therapy such as 0.625 mg daily of conjugated equine estrogen.
• the compound of this invention (VI) is also useful as an antioxidant.
• the compound (VI) can be used to treat, inhibit, or ameliorate atherosclerosis, coronary artery disease, cardiovascular disease, restenosis (particularly resulting from a balloon catheter angioplasty procedure), skin aging and wrinkling, and Alzheimer's disease.
• the compound of this invention (VI) is also useful as in the treatment of carcinomas.
• the compound of this invention (VI) is also useful for preventing free radical generation and is thereby useful in the prophylaxis and retardation of cellular damage caused by free radicals.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Engineering & Computer Science (AREA)
• Rheumatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Steroid Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22842497

Family Applications (1)

Country Status (18)

Families Citing this family (20)

Citations (4)

Family Cites Families (8)

• 1994
  • 1994-04-08 US US08/224,849 patent/US5395831A/en not_active Expired - Lifetime
  • 1994-12-01 US US08/347,742 patent/US5496814A/en not_active Expired - Lifetime
• 1995
  • 1995-02-20 TW TW084101526A patent/TW314468B/zh active
  • 1995-03-29 IL IL11317895A patent/IL113178A/xx not_active IP Right Cessation
  • 1995-04-04 ZA ZA952771A patent/ZA952771B/xx unknown
  • 1995-04-06 KR KR1019960705688A patent/KR970702291A/ko not_active Ceased
  • 1995-04-06 ES ES95915579T patent/ES2128051T3/es not_active Expired - Lifetime
  • 1995-04-06 DE DE69508068T patent/DE69508068T2/de not_active Expired - Fee Related
  • 1995-04-06 NZ NZ283951A patent/NZ283951A/en unknown
  • 1995-04-06 JP JP7526442A patent/JPH09511748A/ja not_active Withdrawn
  • 1995-04-06 CN CN95193322A patent/CN1149298A/zh active Pending
  • 1995-04-06 AU AU22421/95A patent/AU688029B2/en not_active Ceased
  • 1995-04-06 CA CA002186486A patent/CA2186486A1/en not_active Abandoned
  • 1995-04-06 HU HU9602755A patent/HUT76338A/hu unknown
  • 1995-04-06 EP EP95915579A patent/EP0754190B1/en not_active Expired - Lifetime
  • 1995-04-06 AT AT95915579T patent/ATE177111T1/de not_active IP Right Cessation
  • 1995-04-06 DK DK95915579T patent/DK0754190T3/da active
  • 1995-04-06 WO PCT/US1995/004252 patent/WO1995027724A1/en not_active Ceased
  • 1995-05-25 US US08/450,960 patent/US5552395A/en not_active Expired - Lifetime
• 1999
  • 1999-05-11 GR GR990401273T patent/GR3030185T3/el unknown

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events